A Randomised Study Comparing Escitalopram with Venlafaxine XR in Primary Care Patients with Major Depressive Disorder
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
This 8-week, randomised, double-blind study compared the efficacy and tolerability of escitalopram to that of venlafaxine XR in primary care patients with major depressive disorder. The efficacy of escitalopram (10– 20 mg; n = 148) was similar to venlafaxine XR (75– 150 mg; n = 145), based on mean change from baseline to week 8 in Montgomery and Åsberg Depression Rating Scale total score. In ad hoc analyses, escitalopram-treated patients achieved sustained remission significantly faster than did venlafaxine-treated patients. More venlafaxine-treated patients had nausea, constipation, and increased sweating (p < 0.05). When treatment was completed after 8 weeks, significantly more venlafaxine-treated patients had discontinuation symptoms (p < 0.01). Thus escitalopram treatment was similar to venlafaxine treatment with respect to efficacy and was better tolerated by patients in primary care.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Self-citationDevelopment of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Affective disorders and suicide risk: a reexamination
Bostwick, J. M., & Pankratz, V. S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.12.1925 · Cited by 878
Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
Thase, M. E., Entsuah, A. R., & Rudolph, R. L. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.3.234 · Cited by 801
The enduring psychosocial consequences of mania and depression
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.5.720 · Cited by 658
The Role of the Primary Care Physician in Patientsʼ Adherence to Antidepressant Therapy
LIN, E. H. B., KORFF, M. V., KATON, W., BUSH, T., SIMON, G. E., WALKER, E., & ROBINSON, P. (1995) · Medical Care · doi:10.1097/00005650-199501000-00006 · Cited by 587
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice.
Bhuiyan, P. S., & Rege, N. N. (2001) · PubMed · Cited by 527
Owens, M. J., Knight, D. L., & Nemeroff, C. B. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01145-3 · Cited by 516
Bauer, M., Whybrow, P. C., Angst, J., Versiani, M., Möller, H.-J., & WFSBP Task Force on Treatment Guide (2002) · The World Journal of Biological Psychiatry · doi:10.3109/15622970209150599 · Cited by 346
Pérez, V., Gilaberte, I., Faries, D., Alvarez, E., & Artigas, F. (1997) · The Lancet · doi:10.1016/s0140-6736(96)08007-5 · Cited by 300
A Randomized Trial of Relapse Prevention of Depression in Primary Care
Katon, W., Rutter, C., Ludman, E. J., Von Korff, M., Lin, E., Simon, G., Bush, T., Walker, E., & Unützer, J. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.3.241 · Cited by 295
Lepola, U. M., Loft, H., & Reines, E. H. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000074988.54339.7c · Cited by 254
Wade, A., Michael Lemming, O., & Bang Hedegaard, K. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200205000-00001 · Cited by 231
Reboxetine: the first selective noradrenaline re-uptake inhibitor
Kasper, S., Giamal, N. E., & Hilger, E. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.4.771 · Cited by 210
Emergence of Adverse Events Following Discontinuation of Treatment With Extended-Release Venlafaxine
Fava, M., Mulroy, R., Alpert, J., Nierenberg, A. A., & Rosenbaum, J. F. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.12.1760 · Cited by 198
Takahashi, A. (1998) · International Clinical Psychopharmacology · doi:10.1097/00004850-199801000-00048 · Cited by 183
Michelson, D., Fava, M., Amsterdam, J., Apter, J., Londborg, P., Tamura, R., & Tepner, R. G. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.4.363 · Cited by 181
Gorman, J. M., Korotzer, A., & Su, G. (2002) · CNS Spectrums · doi:10.1017/s1092852900028595 · Cited by 169
Montgomery, S. A., Rasmussen, J. G. C., & Tanghøj, P. (1993) · International Clinical Psychopharmacology · doi:10.1097/00004850-199300830-00008 · Cited by 163
Self-citationRudolph, R. L., & Feiger, A. D. (1999) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00067-1 · Cited by 158
Problems with currently available antidepressants.
Gumnick, J. F., & Nemeroff, C. B. (2000) · PubMed · Cited by 95
Hindmarch, I., Kimber, S., & Cockle, S. M. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015060-00001 · Cited by 84
Bitsios, P., Szabadi, E., & Bradshaw, C. M. (1999) · Psychopharmacology · doi:10.1007/s002130050949 · Cited by 79
Cunningham, L. A. (1997) · Annals of Clinical Psychiatry · doi:10.1023/a:1026277907818 · Cited by 78
Comparison of escitalopram and citalopram efficacy: A meta-analysis
Auquier, P., Robitail, S., Llorca, P.-M., & Rive, B. (2003) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500310003408 · Cited by 76
Clinically relevant effect sizes in depression
Montgomery, S. (1994) · European Neuropsychopharmacology · doi:10.1016/0924-977x(94)90093-0 · Cited by 68
Self-citationAbdelmawla, Langley, Szabadi, & Bradshaw (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00031.x · Cited by 58
Montgomery, S. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(98)00049-2 · Cited by 38
Self-citationPlacebo-controlled efficacy of antidepressants in continuation treatment
Montgomery, S. A., Roberts, A., & Patel, A. G. (1994) · International Clinical Psychopharmacology · doi:10.1097/00004850-199403001-00008 · Cited by 32
Self-citationLinden, M., Ludewig, K., Munz, T., & Dierkes, W. (2003) · Pharmacopsychiatry · doi:10.1055/s-2003-43050 · Cited by 12
Bielski, R., Ventura, D., Chang, C., & Korotzer, A. R. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(03)91917-1 · Cited by 11
Research works printed but not linked: 1
- 10.1097/00004850-200307000-00003 · DOI · Paper page
Cited by
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,510
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707
“…Keller et al, 1998; Sackeim et al, 2000; Alpert et al, 2002, 2004; Rush et al, 2003a; Bielski et al, 2004; Fava et al, 2004; Goldstein et al, 2004; Montgomery et al, 2004; Nelson et al, 2004; Perlis et al, 2004; Prudic et al, 2004; Trivedi et al, 2004a) and in pooled or meta-analyses (Lepola et…”
BackgroundStahl, S. M., Grady, M. M., Moret, C., & Briley, M. (2005) · CNS Spectrums · doi:10.1017/s1092852900019726 · Cited by 458
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Metadata
- Authors
- Montgomery, S. A., Huusom, A. K. T., & Bothmer, J.
- Affiliations
- Imperial College London (GB)
- Lundbeck (Denmark) (DK)
- Lundbeck (Germany) (DE)
- ORCID
- Montgomery, S.A.
- Venue
- Neuropsychobiology
- Publisher
- S. Karger AG
- Published
- 2004
- Volume
- 50
- Issue
- 1
- Pages
- 57-64
- ISSN
- 0302-282X (ISSN-L)
- 1423-0224
- OpenAlex
- W1996105921
- Semantic Scholar
- 0534a384a0087b65059d7d19c725f818f8d41407
- Cited by
- 168
- References
- 34
- Citations by year
- 2024: 3 · 2023: 4 · 2022: 2 · 2021: 3 · 2020: 2 · 2019: 5 · 2018: 4 · 2017: 2 · 2016: 5 · 2015: 5 · 2014: 3 · 2013: 7 · 2012: 8
- FWCI
- 12.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Neuropsychobiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- escitalopram, major depressive disorder, antidepressant efficacy, drug tolerability, primary care, sustained remission, discontinuation symptoms, nausea, sweating, constipation
- MeSH terms
- Venlafaxine Hydrochloride, Adult, Constipation, Cyclohexanols, Delayed-Action Preparations, Depressive Disorder, Double-Blind Method, Female, Humans, Male, Middle Aged, Nausea, Primary Health Care, Psychiatric Status Rating Scales, Sweating, Citalopram, Treatment Outcome, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.